Skip to Main Content

Paper Details

Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Neuro Oncol
60
2015
Author NameAffiliation
Kenneth R HessUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
Kenneth R HessUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
Morris D GrovesUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
John F de GrootUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
Vinay K PuduvalliUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
Howard ColmanUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
Howard ColmanUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
Kenneth AldapeUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
Kenneth AldapeUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
Wai-Kwan Alfred YungUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
Wai-Kwan Alfred YungUniversity of Texas MD Anderson Cancer Center, Kaiser Permanente Redwood City Medical Center, Ohio State University Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, Utah (H.C.) Atlanta Regional Community Clinical Oncology Program, Medical University of South Carolina Brain & Spine Tumor Program, The University of Kansas Cancer Center, Saint Francis Medical Center, University of Texas Health Science Center, West Virginia University, Keck School of Medicine, University of Southern California, U.S.C Norris Cancer Hospital, University of Louisville, James Graham Brown Cancer Center
  • 1 - 11

Datasets